Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Ther ; 22(4): 702-12, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24336173

RESUMO

Pompe disease is an autosomal recessive disorder caused by mutations in the acid-α glucosidase (GAA) gene. Lingual dysfunction is prominent but does not respond to conventional enzyme replacement therapy (ERT). Using Pompe (Gaa(-/-)) mice, we tested the hypothesis that intralingual delivery of viral vectors encoding GAA results in GAA expression and glycogen clearance in both tongue myofibers and hypoglossal (XII) motoneurons. An intralingual injection of an adeno-associated virus (AAV) vector encoding GAA (serotypes 1 or 9; 1 × 10(11) vector genomes, CMV promoter) was performed in 2-month-old Gaa(-/-) mice, and tissues were harvested 4 months later. Both serotypes robustly transduced tongue myofibers with histological confirmation of GAA expression (immunochemistry) and glycogen clearance (Period acid-Schiff stain). Both vectors also led to medullary transgene expression. GAA-positive motoneurons did not show the histopathologic features which are typical in Pompe disease and animal models. Intralingual injection with the AAV9 vector resulted in approximately threefold more GAA-positive XII motoneurons (P < 0.02 versus AAV1); the AAV9 group also gained more body weight over the course of the study (P < 0.05 versus AAV1 and sham). We conclude that intralingual injection of AAV1 or AAV9 drives persistent GAA expression in tongue myofibers and motoneurons, but AAV9 may more effectively target motoneurons.


Assuntos
Terapia Genética , Doença de Depósito de Glicogênio Tipo II/genética , Doença de Depósito de Glicogênio Tipo II/terapia , Neurônios Motores/metabolismo , alfa-Glucosidases/genética , Animais , Dependovirus/genética , Regulação Enzimológica da Expressão Gênica , Técnicas de Transferência de Genes , Glicogênio , Doença de Depósito de Glicogênio Tipo II/patologia , Humanos , Injeções Intramusculares , Camundongos , Neurônios Motores/patologia , Músculo Esquelético/metabolismo , Miofibrilas/genética , Miofibrilas/metabolismo , Regiões Promotoras Genéticas , alfa-Glucosidases/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...